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a b s t r a c t
The use of sutureless valves in the case of a heavily calciﬁed aortic homograft allows for
relatively quick and safe replacement. Due to the nitinol frame, which is self-anchored in the
aortic valve annulus and in the sinotubular junction (STJ), no complete annular decalciﬁca-
tion or ﬁxation with stitches is required. In conditions of signiﬁcant calciﬁcation this may
represent a technical problem.
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.Introduction
Aortic valve stenosis is the most common valve disease in
Europe and North America. Calciﬁed aortic stenosis occurs
in 2–7% of the population older than 65 years. According to
various literature data up to 30–60% of symptomatic patients
with signiﬁcant aortic stenosis are not indicated for surgical
intervention, most often due to old age or associated
comorbidities [1–3]. In this case, the prognosis of untreated
patients with symptomatic severe aortic stenosis is poor;
the 5-year survival rate is between 15 and 50% [1,3]. The
only effective and efﬁcient treatment of symptomatic aortic* Corresponding author . Tel.: +420 387874201.   
E-mail addresses: canadyova.julia@gmail.com (J. Čanádyová), a.mo
1 Tel.: +420 387874201.
http://dx.doi.org/10.1016/j.crvasa.2015.02.001
0010-8650/# 2015 The Czech Society of Cardiology. Published by Elsevalve stenosis is valve replacement (class I recommendation,
ESC/EACTS guidelines on the management of valvular heart
disease (2012)) [4].
The conventional treatment of severe aortic stenosis is
surgical replacement of the valve through a median sternotomy
using cardiopulmonary bypass (CPB). In order to minimize
periprocedural risks and to accelerate postoperative rehabilita-
tion, less invasive approaches have been developed and are
increasingly used while maintaining quality and safety. At
the same time the occurrence of older and sicker patients is
also increasing [5,6]. The current patients are often with a
heavily calciﬁed valve, aortic root or diffuse atherosclerosis
of the aortic wall after a previous aortic valve replacement.
This has led to the development of less invasive therapeutickracek@seznam.cz (A. Mokráček).
vier Sp. z o.o. All rights reserved..
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 3 6 2 – e 3 6 5 e363concepts, including transcatheter aortic valve implantation
(TAVI) and sutureless bioprosthesis.
Case report
We describe the case of a 70-year-old female patient with
hypertension, dyslipidemia, hypothyroidism on replace-
ment therapy for thyroid lobectomy in 2012 and severe
stenosis of the aortic homograft. In 2005 the patient
underwent persistent foramen ovale (PFO) closure and
aortic valve replacement with an aortic homograft due to
infective endocarditis. The patient was admitted to our
department in March 2014 for worsening dyspnea, NYHA II–
III. She was without chest pain and syncope. An echocar-
diographic examination conﬁrmed severe stenosis of the
aortic homograft, with peak gradient (PG) 100 and mean
gradient (MG) 58 mmHg and indexed aortic valve area (AVAi)
0.35 cm2/m2. Coronary angiogram examination excluded
signiﬁcant coronary artery disease. The logistic EuroSCORE
was 10.77%. The patient was indicated for valve replace-
ment. Because of the higher operative risk, during the
decision-making process the patient was considered for
transcatheter aortic valve implantation (TAVI) or implanta-
tion of a sutureless bioprosthesis. Based on preoperative CT
scans of the aorta, which revealed a signiﬁcant calciﬁcation
of the valve, aortic root and ascending aorta, we decided to
use the sutureless valve (Fig. 2). A major reason was the high
calcium score and in our opinion it was also due to the
higher risk of paravalvular insufﬁciency in TAVI.Fig. 1 – (A) Perceval S valve. (B) The holder device and valve coll
prosthesis into the annulus.Surgical procedure
The procedure was performed in a standard operating room;
general anesthesia and systemic heparinization were per-
formed. The heart was exposed through a median sternotomy
because of reoperation. The ascending aorta and right atrium
appendage were cannulated and the patient was placed on
cardiopulmonary bypass (CPB). After aortic cross-clamping the
antegrade infusion of cold blood cardioplegia was delivered.
The aortic bioprosthesis Perceval S is made from a bovine
pericardial valve mounted on a compressible and expandable
metal frame in nitinol, with unique features and mechanical
behavior (Fig. 1A). The valve prosthesis is loaded and collapsed
into a delivery device (Fig. 1B). Collapsing increases the
visibility and preserves the integrity of the valve leaﬂets.
The reduced collapsed proﬁle prevents trauma to the aortic
wall, enabling a full and direct view. To ensure correct
positioning of the prosthesis, three guiding threads are
temporarily positioned in the lowest part of the native leaﬂet
insertion line for each valve sinus and the corresponding part
of the bioprosthesis as reference points for accurate alignment
of the inﬂow section of the prosthesis with the insertion plane
of the native leaﬂets (Fig. 1C). The temporary guiding threads
suture the valve by guiding it along the annulus axis even in
narrow spaces. Once the prosthesis is deployed and released,
the guiding threads are removed (Fig. 1D) [5].
A transverse aortotomy was done 1 cm distal to the sino-
tubular junction so as to leave an edge free for closure of the
aortotomy after implantation of the device and to preventapsing. (C) Three guide threads. (D) Completely deployed
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The calciﬁed aortic homograft was removed and the aortic
annulus was decalciﬁed. After measuring the size of the valve –
as the free passage of the transparent portion of the sizer
through the annulus into the left ventricle but not free passageFig. 2 – Preoperative CT angiogram showed calcifiedof the white portion into the ventricle – the prosthesis ‘‘M’’ was
chosen.
During the valve collapse, the three guiding threads were
positioned. The release device is inserted into the aorta down
to the point where it was blocked by pulling the previously aortic homograft, root and the ascending aorta.
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the delivery device, was released in two phases, the inﬂow
section opens ﬁrst, while full release of the prosthesis is
obtained only after opening of the outﬂow part. Once the
prosthesis was completely deployed, the guiding threads were
removed. To optimize the area of contact between the
prosthesis and the aortic annulus, a post-dilatation is carried
out with a balloon catheter at a pressure of four atmospheres.
After weaning from CPB, the sternum and wound were
closed in the standard manner. The duration of the ischemic
arrest was 34 min and CPB time was 61 min. The control
intraoperative transesophageal echocardiography was favor-
able, with no paravalvular leak or other dysfunctions of the
prosthesis with a gradient PG/MG 20/14 mmHg.
The patient was transported to the intensive care unit and
further course was uneventful. The patient was discharged on
the eighth postoperative day.
Discussion
In order to minimize mortality and to extend the indications of
surgical treatment for high-risk, otherwise inoperable patients,
less invasive alternative approaches using innovative technol-
ogies have been developed [6]. Transcatheter aortic valve
implantation (TAVI) and sutureless valve represent two of the
most important advances in the treatment of aortic valve
diseases in recent years [6]. Similar to conventional surgical
replacement of the valve, sutureless bioprosthesis requires
valve excision (risk reduction of paravalvular insufﬁciency
compared with TAVI) and annular decalciﬁcation, but perma-
nent ﬁxation sutures are not required [6]. The possibility of
avoiding sutures placement and their tidying may lead to
shorter procedural times. In cardiac surgery, prolonged CPB and
cross-clamp time duration are strong independent risk factors
for postoperative mortality and morbidity [7,8].
These advantages could be of beneﬁt to patients who have
no fundamental contraindications for using cardiopulmonary
bypass and are undergoing complex, combined procedures or
re-operations. Patients with a small aortic annulus or heavy
calciﬁcation of the annulus and aortic root, where sutures
positioning may represent technical problems and complica-
tions, are another potential group that could beneﬁt.
Conclusion
Sutureless aortic bioprosthesis represents a new generation of
bioprosthesis and another therapeutic option in the spectrum
of aortic valve replacement.
They combine the advantages of stentless valves in terms
of hemodynamic parameters (a more efﬁcient effective oriﬁce
area – EOA) and simple and safe implantation.
The potential to reduce operative time may be beneﬁcial in
sicker elderly patients undergoing combined surgeries and
reoperation, and their construction enables and supports
minimally invasive approaches in cardiac surgery (insertion
through the partial sternotomy or right thoracotomy).Conﬂict of interest
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